Results

Regeneron Pharmaceuticals Inc.

06/25/2021 | Press release | Distributed by Public on 06/24/2021 23:03

Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression